Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.6K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.6K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

539
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
539
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

54
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
54
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

211
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
211
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.6K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tiny Subsamples and Upsampling Tame Big Data Evolutionary Analysis in Phylogenomics.

bioRxiv : the preprint server for biology·2026
Same author

The IMPACT-FH Renewal Protocol: Evaluating FH Cascade Testing Implementation in Primary Care through a Pragmatic Trial, Economic Evaluation, and Mixed-Methods Sustainability Assessment.

Public health genomics·2026
Same author

The genetic foundations of convergent traits.

Nature reviews. Genetics·2026
Same author

Population Screening for Type 1 Diabetes in Pediatrics via Well-Child Visits: Barriers and Facilitators to Implementation.

Diabetes spectrum : a publication of the American Diabetes Association·2026
Same author

Complete genomes of a multi-generational pedigree to expand studies of genetic and epigenetic inheritance.

bioRxiv : the preprint server for biology·2025
Same author

An Evolutionary Metric for Estimating PhyloAges from Bulk Sequencing of Hematopoietic Stem Cells Reveals the Tempo of Blood Aging in Cancer and Longevity.

Journal of molecular evolution·2025

Related Experiment Video

Updated: Nov 15, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.0K

Common Treatment, Common Variant: Evolutionary Prediction of Functional Pharmacogenomic Variants.

Laura B Scheinfeldt1, Andrew Brangan1, Dara M Kusic1

  • 1Coriell Institute for Medical Research, Camden, NJ 08003, USA.

Journal of Personalized Medicine
|March 6, 2021
PubMed
Summary

This study introduces XGB-PGX, a new computational method for pharmacogenetic variant identification. It improves drug efficacy and safety predictions by analyzing global genomic data, benefiting underrepresented populations.

Keywords:
adaptationhuman evolutionmachine learningpharmacogenomic

More Related Videos

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.2K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.9K

Related Experiment Videos

Last Updated: Nov 15, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.0K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.2K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.9K

Area of Science:

  • Genomics
  • Computational Biology
  • Pharmacogenetics

Background:

  • Pharmacogenomics research is often biased towards European populations.
  • Existing methods lack comprehensive global population data.
  • Personalized medicine requires accurate identification of pharmacogenetic variants across diverse ancestries.

Purpose of the Study:

  • To develop a novel in silico method for identifying pharmacogenetic variants.
  • To overcome ascertainment bias in pharmacogenomic research.
  • To improve drug efficacy and minimize toxicity through personalized genetic testing.

Main Methods:

  • Leveraged whole genome sequencing data from global populations.
  • Integrated evolutionary characteristics and annotated protein features.
  • Developed and applied a machine learning model (XGB-PGX).

Main Results:

  • XGB-PGX outperformed existing pharmacogenetic prediction methods.
  • Identified over 2000 new pharmacogenetic variants.
  • Highlighted the prevalence of common functional variants across populations.

Conclusions:

  • Pharmacogenetic testing should focus on individuals, not race or ethnicity.
  • Emphasized the importance of common genetic variation in drug response.
  • XGB-PGX offers significant benefits for underrepresented genomic research communities.